1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,133 | 0,164 | 22:32 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:34 | Cantargia (OMX: CANTA) breast cancer study fully recruited | 141 | Edison Investment Research | Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy,... ► Artikel lesen | |
| 15:26 | Cantargia's TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited | 162 | ACCESS Newswire | TRIFOUR is Cantargia's first randomized, controlled study of nadunolimabFirst preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB)... ► Artikel lesen | |
| Do | Cantargia to Participate at H.C. Wainwright's Annual Autoimmune & Inflammatory Virtual Conference | 161 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 6, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| Mi | Cantargia (OMX: CANTA) reports positive CAN10 update | 175 | Edison Investment Research | Cantargia has reported encouraging pharmacokinetic data from the first cohort in the multiple ascending dose portion of the CAN10 study. Importantly, the data align with the single dose portion of the... ► Artikel lesen | |
| Mi | Cantargia Reports Promising CAN10 Phase 1 Data From First Multiple Dose Cohort, and FDA and Key Opinion Leader Feedback | 201 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 5, 2025 / Cantargia (STO:CANTA)Promising multiple dose PK data continue to support 4-weekly dosingFDA advice received supporting phase 2 design in HSStrong Key Opinion... ► Artikel lesen | |
| 21.02. | Cantargia Publishes Full Year Report for 2024 | 227 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / February 21, 2025 / Cantargia (STO:CANTA) Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) full year report for 2024 is now available on the company's web... ► Artikel lesen | |
| 19.02. | Cantargia to Participate in Leerink Partners Global Healthcare Conference | 217 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 19, 2025 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one meetings... ► Artikel lesen | |
| 13.02. | Invitation to Presentation of Cantargia's Year-End Report 2024 | 164 | ACCESS Newswire | LUND, SE / ACCESSWIRE / February 13, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) invites investors, analysts and the press to a presentation of the interim October... ► Artikel lesen | |
| 05.02. | Cantargia Announces Management Changes | 290 | ACCESS Newswire | Göran Forsberg, CEO, steps downDamian Marron, Board Director, to assume role of Interim CEORecruitment process for new permanent CEO underway LUND, SWEDEN / ACCESS Newswire / February 5, 2025 / Cantargia... ► Artikel lesen | |
| 31.01. | Cantargia Announces Changes in Number of Shares and Votes | 226 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / January 31, 2025 / Cantargia AB's (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia AB... ► Artikel lesen | |
| 18.12.24 | Cantargia Publishes Strong Preclinical Effects and Clinical Monotherapy Results on Nadunolimab in Pancreatic Cancer in Journal for Immunotherapy of Cancer | 330 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 18, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of preclinical and clinical results using the IL1RAP... ► Artikel lesen | |
| 11.12.24 | Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational Results on Nadunolimab Treatment in Advanced Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium | 339 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / December 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported updated results from the phase 1b study in 15 advanced triple negative... ► Artikel lesen | |
| 02.12.24 | Extraordinary General Meeting in Cantargia AB | 207 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 02, 2024 / Cantargia (STO:CANTA) Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase... ► Artikel lesen | |
| 02.12.24 | Cantargia AB: Extraordinary general meeting in Cantargia AB (publ) | 307 | GlobeNewswire (Europe) | Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, 2024 to increase the company's share capital through the issuance of new shares... ► Artikel lesen | |
| 02.12.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.12.2024 | 299 | Xetra Newsboard | Das Instrument F1S AU000000OAR8 OAR RESOURCES LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 02.12.2024 und ex Kapitalmassnahme am 03.12.2024 The instrument F1S AU000000OAR8 OAR RESOURCES LTD. EQUITY... ► Artikel lesen | |
| 29.11.24 | Cantargia Expands the CAN10 Phase 1 Clinical Program Building on Positive Results | 284 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 29, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study... ► Artikel lesen | |
| 15.11.24 | Cantargia Publishes Interim Report for Third Quarter 2024 | 233 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 15, 2024 / Cantargia (STO:CANTA) Cantargia AB's ("Cantargia") interim report for the period January until September 2024 is now available on the company's web page... ► Artikel lesen | |
| 13.11.24 | Cantargia Presents Nomination Committee Ahead of 2025 AGM | 208 | ACCESS Newswire | LUND, SE / ACCESSWIRE / November 13, 2024 / Cantargia (STO:CANTA) Cantargia AB (publ) hereby provides notification that the Nomination Committee (NC) has been appointed ahead of the 2025 Annual General... ► Artikel lesen | |
| 11.11.24 | Cantargia Results Showing Efficacy of CAN10 in Models of Myocarditis Published in Circulation: Heart Failure | 584 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced the publication of CAN10 results in disease models of myocarditis... ► Artikel lesen | |
| 06.11.24 | Notice of extraordinary general meeting in Cantargia AB | 309 | ACCESS Newswire | LUND, SE / ACCESSWIRE / November 6, 2024 / Cantargia (STO:CANTA) The shareholders of Cantargia AB (publ) are invited to the extraordinary general meeting on Monday, 2 December 2024, at 10.00 CET at... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 98,05 | -3,49 % | Novo Nordisk, NetraMark, BioNTech - Wie drei Pioniere den Weg in die Medizin von morgen ebnen | Am 6. Januar 2025 hat die FDA neue Richtlinien für KI-gestützte klinische Studien ankündigt, um die Zulassung lebensrettender Therapien zu beschleunigen. Damit rücken Unternehmen in den Fokus, die Technologie... ► Artikel lesen | |
| EVOTEC | 6,375 | -3,34 % | Evotec massiv unter Druck: Gute News verpuffen - Aktie mit neuem Verkaufssignal | Lange Zeit war es ruhig bei Evotec. Heute hat der Hamburger Wirkstoffforscher aber positive News aus der langjährigen Neurologie-Partnerschaft mit Bristol Myers Squibb melden können. Der Aktie verlieh... ► Artikel lesen | |
| QIAGEN | 36,525 | +0,04 % | Qiagen NV-Aktie läuft heute schlechter (36,415 €) | Im Minus liegt aktuell das Wertpapier von Qiagen NV . Das Papier kostete zuletzt 36,42 Euro. Die Qiagen NV-Aktie verzeichnet gegenwärtig ein Minus von 1,29 Prozent. Sie hat sich um 48 Cent gegenüber... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 689,80 | +5,73 % | Regeneron, Sanofi Present Positive Phase 2/3 Trial Results For Dupixent In Bullous Pemphigoid | PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab)... ► Artikel lesen | |
| BRAIN BIOTECH | 2,300 | -2,13 % | EQS-DD: BRAIN Biotech AG: Michael Schneiders, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.03.2025 / 11:25... ► Artikel lesen | |
| SCORPIUS | 0,170 | 0,00 % | XFRA 1HB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCORP.HLDGS.NEW... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,006 | -6,33 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,060 | +7,12 % | Burcon NutraScience Corporation: Burcon Announces its Alliance Partner Completes Acquisition of Protein Production Facility | Vancouver, British Columbia--(Newsfile Corp. - March 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| CSL | 146,08 | -2,55 % | Dividendenbekanntmachungen (07.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACUSHNET HOLDINGS CORP US0050981085 0,235 USD 0,2177 EUR AEW UK REIT PLC GB00BWD24154 0,02 GBP EUR AMERISAFE INC US03071H1005 0... ► Artikel lesen | |
| MANNKIND | 4,580 | -0,15 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,166 | -5,66 % | TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain? | ||
| OCULAR THERAPEUTIX | 6,930 | -0,26 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,414 | -7,17 % | Adaptimmune Therapeutics Aktie: Vertrauensbruch im Anmarsch? | Die Adaptimmune Therapeutics Aktie verzeichnet zum 01. März 2025 einen stabilen Kurs von 0,52 EUR, bleibt jedoch unter Druck. Im vergangenen Monat musste das biopharmazeutische Unternehmen einen Rückgang... ► Artikel lesen | |
| CODEXIS | 2,326 | -10,68 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| TELO GENOMICS | 0,068 | -10,53 % | Telo Genomics Corp.: Telo Genomics Announces Expanded Partnership with Trusted Health Advisors | Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that, further to its engagement with Trusted Health... ► Artikel lesen |
CANTARGIA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,151 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.
